Ipamorelin
Ipamorelin was introduced in Phase II clinical trials for the treatment of intestinal pseudo-obstruction (POI), sponsored by Helsinn Therapeutics. However, in patients undergoing intestinal resection, ipamorelin does not shorten the time for the first meal intake compared to placebo [30]. The Phase II clinical trial below showed no significant difference in measurable colonic functions between ipamorelin and placebo [31]. Due to these disappointing results, its development was halted.